The Atlas Study: A Big Change
By: Gwyn Bevel
Updated: March 1, 2013
FOR DECADES, IT'S BEEN PRESCRIBED TO HELP WOMEN FIGHT BREAST CANCER FROM COMING BACK. NOW A NEW STUDY SHOWS, STAYING ON THE DRUG LONGER MAY NOT HAVE THE EFFECTS DOCTORS ONCE BELIEVED.
TONIGHT'S HEALTHCAST TELLS US ABOUT COULD CHANGE TREATMENT FOR BREAST CANCER SURVIVORS.
TAMOXIFEN IS HELPING HER REDUCE THE RISK OF BREAST CANCER RECURRENCE. IT'S NORMALLY A FIVE YEAR TREATMENT.
Breast Cancer Survivor Carol Yancey says, "For the last, oh gosh, couple of decades, I guess, we've been using five years as our standard."
THE BELIEF WAS THE BENEFIT OF STAYING ON IT LONGER WAS OUTWEIGHED BY A WOMAN'S RISK, OF THINGS LIKE UTERINE CANCER AND BLOOD CLOTS.
Dr. Steven Isakoff says, "I think this study goes a long way to show that actually doesn't seem to be the case."
PRESENTED AT THE RECENT BREAST CANCER SYMPOSIUM, THE ATLAS STUDY, INVOLVED MORE THAN 68-HUNDRED WOMEN WITH E-R-POSITIVE BREAST CANCER, WHO'D BEEN ON TAMOXIFEN FOR FIVE-YEARS. SOME WERE RANDOMLY ASSIGNED TO STAY ON THE DRUG FOR FIVE MORE YEARS. THE RESULTS FOUND THE WOMEN ON TAMOXIFEN FOR TEN YEARS HAD THEIR RISK OF RECURRENCE CUT BY 25-PERCENT.
THEIR RISK OF DYING FROM BREAST CANCER ALSO WENT DOWN 29-PERCENT.
Dr. Kent C. Osborne says, "I guess I'm a little bit surprised at the findings."
BUT DOCTORS WARN EXTENDING TAMOXIFEN ISN'T RIGHT FOR ALL PATIENTS.
Isakoff: "For someone who has a generally low risk of recurrence, we'll have to weigh the risks and benefits."
NOW, THE CHALLENGE COULD BE SPREADING THE WORD.
Osborne: "But I think it will just naturally find its spot in the treatment."
IF CAROL'S DOCTOR SAYS THIS WILL CONTINUE TO BE HER DAILY ROUTINE FOR SIX MORE YEARS, INSTEAD OF ONE MORE YEAR.
yancey: "I would do it, if it means that this doesn't come back, and I don't have to go through any of that again."
THE ATLAS STUDY FOUND TEN YEARS OF TAMOXIFEN DOES HAVE SOME SIDE EFFECTS, THE BIGGEST, BEING, THE RISK OF ENDOMETRIAL CANCER, BUT BECAUSE IT'S GENERALLY CURABLE, RESEARCHERS SAY THAT RISK IS HEAVILY OUTWEIGHED BY THE POSSIBLE BENEFITS OF EXTENDING THE DRUG TREATMENT.
